Skip to content
Review Open access

Immune checkpoint inhibitors in advanced cholangiocarcinoma: a systematic review of efficacy, safety, and emerging biomarkers

Jul 2026 · Journal of the Egyptian National Cancer Institute · Vol 38 · 0 citations · 22 references
Medicine

TL;DR

Triplet and locoregional combinations show encouraging efficacy, warranting further validation, and biomarker-driven selection, particularly HRD/DDR status and ctDNA monitoring, will be critical to optimizing outcomes.

Abstract

Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy often diagnosed at an advanced stage. For over a decade, gemcitabine-cisplatin (GemCis) remained the standard of care with limited survival benefit. The advent of immune checkpoint inhibitors (ICIs) has transformed the therapeutic landscape, but variability in outcomes and a rapidly expanding evidence base require systematic synthesis. A systematic review was conducted following PRISMA 2020 guidelines. The review was not registered in PROSPERO or another prospective registry. PubMed/MEDLINE and Embase were searched from inception through 31 December 2024. Studies evaluating PD-1/PD-L1/CTLA-4 inhibitors alone or in combination for advanced CCA were included. Risk of bias was assessed using ROBINS-I for non-randomized studies and Cochrane RoB 2 for randomized controlled trials. A narrative synthesis was performed due to clinical and methodological heterogeneity. Fifty-one studies (≈ 4,800 patients) met inclusion criteria, including 8 randomized controlled trials and 43 non-randomized studies. First-line chemo-immunotherapy with durvalumab or pembrolizumab plus GemCis established new standards of care in TOPAZ-1 (mOS 12.9 vs. 11.3 months; HR 0.76) and KEYNOTE-966 (mOS 12.7 vs. 10.9 months; HR 0.83). Triplet regimens (chemotherapy + ICI + tyrosine kinase inhibitor [TKI]) demonstrated high activity (e.g., toripalimab + lenvatinib + GEMOX: ORR 80%, mOS 22.5 months). Second-line ICI monotherapy yielded modest ORRs (3–22%), while ICI + TKI combinations showed ORRs of 9–28%. Grade ≥ 3 treatment-related adverse events ranged from 10 to 17% (ICI monotherapy) to 70–75% (chemo-ICI). PD-L1 expression was not predictive in chemo-ICI; homologous recombination deficiency (HRD)/DNA damage response (DDR) mutations and circulating tumor DNA (ctDNA) clearance emerged as promising biomarkers. ICIs combined with chemotherapy have redefined first-line treatment for advanced CCA. Triplet and locoregional combinations show encouraging efficacy, warranting further validation. Biomarker-driven selection, particularly HRD/DDR status and ctDNA monitoring, will be critical to optimizing outcomes.

Read PDF

Similar papers

Review Open access Sep 2026

Efficacy and safety of PD-1 inhibitors plus chemotherapy for advanced unresectable gastroesophageal cancer: a systematic review and meta-analysis of phase III randomized controlled trials

Objective The FDA approval of immune checkpoint inhibitors for advanced gastroesophageal cancer (GEC) independent of programmed death-ligand 1 (PD-L1) expression status has sparked notable clinical controversy, highlighting the urgent need for evidence-based evaluation of the efficacy and safety of various PD-1 inhibit...

Chen-Feng Hua, Rui Zhang, Xiu-Li Mo et al. · 0 citations
Review Oct 2026

The Efficacy of Immune-checkpoint Inhibitors in Combination with Definitive Chemoradiotherapy in Non-metastatic Esophageal SCC: A Systematic Review and Meta-analysis.

BACKGROUND Inoperable esophageal squamous cell carcinoma (ESCC) remains a challenging malignancy. Immune checkpoint inhibitors (ICIs) have shown activity in esophageal cancer. This systematic review evaluated the efficacy and safety of adding immune checkpoint inhibitors to definitive chemoradiotherapy (dCRT) in this s...

R. Ghalehtaki, Alireza Shariati, Z. Moradi et al. · 0 citations
Review Open access Sep 2026

Immune checkpoint inhibitor-based therapy in gynecologic clear cell carcinoma: A systematic review and meta-analysis

Introduction: Gynecologic clear cell carcinoma (CCC) is an uncommon histologic entity for which therapeutic options remain limited, and the clinical activity of immune checkpoint inhibitor (ICI)-based treatment has not been clearly defined. Objective: To synthesize the available evidence on efficacy and safety of ICI-c...

Hwisu Jung, Hye Lim Jung, Y. Kwon et al. · 0 citations
Review Open access Dec 2024

Addition of immune checkpoint inhibitor to standard of care chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis

Background: Preliminary findings from this study were previously published as a conference abstract (https://doi.org/10.1158/2326-6074.IO2025-B039). Immune checkpoint inhibitors (ICIs) have shown activity in nasopharyngeal carcinoma (NPC), but their efficacy and safety when integrated with standard chemoradiotherapy (C...

R. Srinivasmurthy, J. Ta, S. Afifi et al. · 3 citations
Review Sep 2026

Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer: A Systematic Review, Meta-Analysis, and GRADE Assessment of Randomized Evidence.

OBJECTIVES Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to eva...

M. Amjad, M. Rafique, S. F. Hussain et al. · 0 citations
Review Open access Nov 2026

Efficacy of prolonged adjuvant imatinib in gastrointestinal stromal tumors: a systematic review and exploratory network meta-analysis

Three years of adjuvant imatinib is the established standard for patients with high-risk gastrointestinal stromal tumors (GIST), but recurrence after treatment cessation raises questions about longer treatment durations. This study evaluated evidence on extended adjuvant therapy, emphasizing treatment beyond 3 ye...

Feng-Xiang Zhang, Ze-Qun Chen, Zhou-Sheng Su et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.